709 related articles for article (PubMed ID: 31129129)
1. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
[TBL] [Abstract][Full Text] [Related]
2. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F; Loesche C; Valentin MA; Jiang X; Cheng Y; Jarvis P; Peters T; Calonder C; Bruin G; Polus F; Aigner B; Lee DM; Bodenlenz M; Sinner F; Pieber TR; Patel DD
J Allergy Clin Immunol; 2017 Mar; 139(3):923-932.e8. PubMed ID: 27502297
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW study.
Krueger J; Langley RG; Nigen S; Kasparek T; Di Comite G; Ortmann CE; Garcet S; Kolbinger F; Reich K
Exp Dermatol; 2023 Oct; 32(10):1834-1847. PubMed ID: 37272375
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
[TBL] [Abstract][Full Text] [Related]
5. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis.
Tomalin LE; Russell CB; Garcet S; Ewald DA; Klekotka P; Nirula A; Norsgaard H; Suàrez-Fariñas M; Krueger JG
J Allergy Clin Immunol; 2020 Mar; 145(3):922-932. PubMed ID: 31883845
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years.
Reich K; Blauvelt A; Armstrong A; Langley RG; de Vera A; Kolbinger F; Spindeldreher S; Ren M; Bruin G
J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1733-1741. PubMed ID: 31009130
[TBL] [Abstract][Full Text] [Related]
7. Bimekizumab versus Secukinumab in Plaque Psoriasis.
Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
[TBL] [Abstract][Full Text] [Related]
9. A review of secukinumab in psoriasis treatment.
Berg SH; Balogh EA; Ghamrawi RI; Feldman SR
Immunotherapy; 2021 Feb; 13(3):201-216. PubMed ID: 33203276
[TBL] [Abstract][Full Text] [Related]
10. IL-17 Blockade in Psoriasis.
Burkett PR; Kuchroo VK
Cell; 2016 Dec; 167(7):1669. PubMed ID: 27984714
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
[TBL] [Abstract][Full Text] [Related]
12. Anti IL-17 in psoriasis.
Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
[No Abstract] [Full Text] [Related]
13. A novel role of IL-17A in contributing to the impaired suppressive function of Tregs in psoriasis.
Liu Y; Zhang C; Li B; Yu C; Bai X; Xiao C; Wang L; Dang E; Yang L; Wang G
J Dermatol Sci; 2021 Feb; 101(2):84-92. PubMed ID: 33334656
[TBL] [Abstract][Full Text] [Related]
14. IL-17 for therapy.
Kurschus FC; Moos S
J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
[TBL] [Abstract][Full Text] [Related]
15. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis.
Reich K; Blauvelt A; Armstrong A; Langley RG; Fox T; Huang J; Papavassilis C; Liang E; Lloyd P; Bruin G
Br J Dermatol; 2017 Mar; 176(3):752-758. PubMed ID: 27518376
[TBL] [Abstract][Full Text] [Related]
17. Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis.
Pinter A; Gerdes S; Papavassilis C; Reinhardt M
J Dermatolog Treat; 2020 Dec; 31(8):769-775. PubMed ID: 31287332
[No Abstract] [Full Text] [Related]
18. IκBζ is a key player in the antipsoriatic effects of secukinumab.
Bertelsen T; Ljungberg C; Litman T; Huppertz C; Hennze R; Rønholt K; Iversen L; Johansen C
J Allergy Clin Immunol; 2020 Jan; 145(1):379-390. PubMed ID: 31622687
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).
Gelfand JM; Shin DB; Duffin KC; Armstrong AW; Blauvelt A; Tyring SK; Menter A; Gottlieb S; Lockshin BN; Simpson EL; Kianifard F; Sarkar RP; Muscianisi E; Steadman J; Ahlman MA; Playford MP; Joshi AA; Dey AK; Werner TJ; Alavi A; Mehta NN
J Invest Dermatol; 2020 Sep; 140(9):1784-1793.e2. PubMed ID: 32088207
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab (AIN457) for the treatment of psoriasis.
López-Ferrer A; Vilarrasa E; Puig L
Expert Rev Clin Immunol; 2015; 11(11):1177-88. PubMed ID: 26428036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
